WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :

Download Article: Click Here

Search

Track Your Article

Abstract

OPICAPONE: A NOVEL THIRD GENERATION COMT ADJUNCT FOR WEARING OFF IN PARKINSON’S DISEASE

Akhil L. L.*, Soumya R. V. and Prasobh G. R.

Abstract

Opicapone is a potent, reversible, and peripherally-acting thirdgeneration inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine. In June 2016, the European Commission granted a marketing authorization valid throughout the European Union for OPC, indicated as adjunct therapy to levodopa and decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations. In April 2020, the FDA approved the use of Opicapone as adjunctive treatment to levodopa/carbidopa in patients with Parkinson‟s disease (PD) experiencing “off” episodes. Opicapone is marketed as, under the brand name Ongentys as once-daily oral capsules. Almost all individuals with Parkinson‟s disease whom are treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (e.g. carbidopa) will develop motor complications in time. The initial step in the management is changing the levodopa/DDC inhibitor dosage and the use of adjunct drugs. Various options include supplementing with a dopamine agonist, a monoamine oxidase B inhibitor (Selegiline, Rasagiline), a catechol-O- methyl transferase (COMT) inhibitor, or Amantadine, or using a modified-release formulation of levodopa. The newest adjunctive option is Opicapone. This drug is a peripherally selective reversible COMT inhibitor that offers the benefit of a duration of action exceeding 24h, allowing for once-daily administration. Opicapone demonstrates the lowest risk for cytotoxicity in comparison with other catechol-O-methyltransferase inhibitors. This review encompasses the clinical pharmacology, adverse effects, interactions and dosage of Opicapone- a future boon to PD.

Keywords: Parkinson?s disease, Opicapone, COMT inhibitor.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More